RARA CRAFT DATABASE for FDA Medical Devices
510(k)K162281

FDA DEVICE FACTS

CAPI 3 Hb A1c, MULTI-SYSTEM Hb A1C CAPILLARY CONTROLS (2)

Sebia

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEFebruary 17, 2017PRODUCT CODELCP

Indications for use

Intended for use as quality control materials. Same Format 2 levels Same Shelf life 3 years at 2 - 8 °C Same In use storage CAPILLARYS HbA1c: When reconstituted the controls are stable for 1 day at 2-8°C, 6 months at -18°C and -30°C. Do not freeze and thaw the reconstituted controls more than 30 times. When hemolyzed, the controls are stable for 8 hours at 2-8°C, 1 month at - 18°C and -30°C. Do not freeze and thaw a dilution segment with hemolyzed control more than three times. MINICAP HbA1c and CAPI 3 HbA1c: When reconstituted the controls are stable for 1 day at 2- 8°C, 6 months at -18°C and -30°C. Do not freeze and thaw the reconstituted controls more than 30 times. CAPILLARYS HbA1c : When reconstituted the controls are stable for 1 day at 2-8°C, 6 months at -18°C and -30°C. Do not freeze and thaw the reconstituted controls more than 30 times. When hemolyzed the controls are stable for 8 hours at 2-8°C, 1 month at -18°C and -30°C. Do not freeze and thaw a dilution segment with hemolyzed control more than three times. MINICAP HbA1c : When reconstituted the controls are stable for 1 day at 2-8°C, 6 months at -18°C and -30°C. Do not freeze and thaw the reconstituted controls more than 30 times.

K. Standard/Guidance Document Referenced (if applicable): CLSI Guideline, EP05-A2: Evaluation of Precision Performance of Clinical Chemistry Devices CLSI Guideline, EP06-A: Evaluation of the Linearity of Quantitative Analytical Methods CLSI Guideline, EP07-A2: Interference Testing in Clinical Chemistry CLSI Guideline, EP09-A2: Method Comparison and Bias Estimation Using Patient Samples CLSI Guideline, EP14-A2: Evaluation of Matrix Effects

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 31, 2026